BDTX 4933
Alternative Names: BDTX-4933Latest Information Update: 12 Jan 2024
At a glance
- Originator Black Diamond Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein b-raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical CNS cancer
Most Recent Events
- 11 Oct 2023 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 30 Sep 2023 Black Diamond Therapeutics initiates enrollment in a phase I trial in Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater, Recurrent, Monotherapy) in USA (PO)
- 10 May 2023 Black Diamond Therapeutics has patents pending for BDTX 1535 worldwide